Recent Developments
Abbott Withdraws Application for Briakinumab
Due to a reported elevated risk for cardiac events associated with
the investigational biologic, Abbott Laboratories has withdrawn
its US biologics license application (BLA) and European marketing
authorization application (MAA) for briakinumab (ABT-874),
an anti-IL-12/23 monoclonal antibody for the treatment of psoriasis.
Recent clinical trial data reportedly uncovered the elevated
risk. “Briakinumab is a highly effective agent for patients with
moderate to severe psoriatic disease,” said Jerry Bagel, MD,
director of the Psoriasis Treatment Center of Central New Jersey
in East Windsor. “Previous trials indicate that more than 90 percent
of patients receiving briakinumab achieved PASI 75,” he said.
“Despite this encouraging efficacy data, recent concerns over the
apparent increased likelihood of major cardiac adverse events
with briakinumab remind of the importance of exercising caution
with other biologics as well,” noted Dr. Bagel.
In a filing with the Securities and Exchange Commission, Abbott said that following feedback from regulatory authorities indicating the need for further analysis and the potential for additional studies, the company plans to evaluate next steps for briakinumab, including potential resubmission at a later date.
Melanoma Clinics an Essential Asset in Diagnosis
Individuals at high risk for melanoma no doubt need
regular follow-up, but a recent study says it should be
at a melanoma center or qualified institution (Archives
of Dermatology E-pub Jan 17). Investigators retrospectively
reviewed data from 201 melanoma patients
divided into two groups: those who received a diagnosis
while being followed, repeatedly, in the clinic
program for high-risk patients and those diagnosed
after a referral to the clinic because of suspicious
skin lesions. Investigators found that 70 percent of
melanomas diagnosed in patients in the follow-up
program were in situ, compared with 27.9 percent of
those in the referral group. Also, the Breslow index
was significantly lower in the follow-up group than
in the referral group, with a mean of 0.55 vs. 1.72
mm (P<0.001).
Interestingly, most of the melanomas diagnosed in the follow-up group did not match some of the clinical or dermoscopic features characteristic of melanoma, and only 12 percent met all four of the ABCD criteria. In contrast, 63.6 percent of the melanomas detected in the referral group met the criteria.
New Statistics on Hair Restoration Procedures
The International Society of Hair Restoration Surgery
recently released its report on 2008 practice census
facts and figures, which indicated that hair procedures
are on the rise. An estimated 252,002 hair restorations
were performed worldwide in 2008, a 12 percent
increase from 2006. A total of 98,727 of those were
performed in the US. The report estimates the worldwide
market for hair restoration procedures to be
worth $1,268,590,668. Notably, the report also showed
that more than half of both female and male patients
were between the ages of 30 and 49.
Calling Dermatologists
A Southern California non-profit group is seeking a
dermatologist to join its upcoming medical mission to
Nicaragua from August 4-14, 2011. International
Medical Alliance (IMA) recruits doctors from every
medical discipline to volunteer, both in the US and
overseas. The IMA has already assembled a team of
more than 60 doctors, nurses, dentists, and support
personnel for the trip. For more information:
www.internationalmedicalalliance.org.
FDA Updates Device Review Process
FDA announced a series of steps it will take this year to streamline
the review of medical devices. The agency also said it will
create an internal council to “assure timely and consistent science-
based decision making.” Notably, regulators said they
would delay a decision on the most drastic proposals, which
would give the government new power to police device makers.
Those proposals, widely supported by public safety advocates,
included clarifying the FDA's power to revoke approval for products
that prove unsafe or ineffective. Another key proposal would
have established a new subset of devices that would require more
medical data to gain approval. The FDA said it would wait for the
guidance of the Institute of Medicine before making a final decision
on more sweeping changes.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- Recent Developments
Recent Developments
- Recent Developments
Recent Developments
- Recent Developments
Recent Developments
- Recent Developments
Recent Developments